Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 7/20 | 0.56 |
| ▸ | RET | P07949 | 8/20 | 0.52 |
| ▸ | EGFR | P00533 | 5/20 | 0.45 |
| ▸ | MET | P08581 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21246953 | 0.84 | KDR (0.59) | KDRRETEGFRMET | |
| SCHEMBL23749306 | 0.84 | KDR (0.58) | KDRRETEGFRMET | |
| SCHEMBL21750833 | 0.83 | RET (0.59) | KDRRETEGFR | |
| SCHEMBL21246957 | 0.77 | RET (0.61) | KDRRETEGFRMET | |
| SCHEMBL21793293 | 0.77 | KDR (0.61) | KDRRETEGFRMET | |
| SCHEMBL23749325 | 0.77 | KDR (0.54) | KDRRETEGFRMET | |
| SCHEMBL21750981 | 0.76 | KDR (0.61) | KDRRETEGFRMET | |
| SCHEMBL22769716 | 0.75 | EGFR (0.53) | KDRRETEGFRMET | |
| SCHEMBL21265686 | 0.75 | KDR (0.69) | KDRRETEGFRMET | |
| SCHEMBL21750909 | 0.75 | KDR (0.59) | KDRRETEGFRMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12202835-B2 | Substituted aromatic ring-linked dioxinoquinazolines and dioxinoquinolines as kinase inhibitors | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2025-01-21 | — | — | US | disclosed |
| US-20220002308-A1 | AROMATIC RING-LINKED DIOXINO-QUINAZOLINE OR DIOXINO-QUINOLINE COMPOUNDS, COMPOSITIONS AND USE THEREOF | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2022-01-06 | — | — | US | disclosed |
| US-20220002308-A1 | AROMATIC RING-LINKED DIOXINO-QUINAZOLINE OR DIOXINO-QUINOLINE COMPOUNDS, COMPOSITIONS AND USE THEREOF | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2022-01-06 | — | — | US | disclosed |
| EP-3865487-A1 | AROMATIC RING-LINKED DIOXANE-QUINAZOLINE OR -QUINOLINE COMPOUNDS, COMPOSITIONS AND USE THEREOF | Beijing Scitech-MQ Pharmaceuticals Limited (CN) | 2021-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002308-A1 | AROMATIC RING-LINKED DIOXINO-QUINAZOLINE OR DIOXINO-QUINOLINE COMPOUNDS, COMPOSITIONS AND USE THEREOF | MERTK, AXL, TYRO3 | KDR 10/4885RET 4/4885EGFR 58/4885 |
| US-12202835-B2 | Substituted aromatic ring-linked dioxinoquinazolines and dioxinoquinolines as kinase inhibitors | MERTK, AXL, TYRO3 | KDR 8/4885RET 4/4885EGFR 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.